Navigation Links
Trubion Announces Presentations at Upcoming Investor Conferences
Date:3/5/2008

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two March investor conferences:

-- March 10: Sanford Bernstein Biotechnology Conference in Alta, Utah. Dr.

Peter Thompson, president, CEO and chairman, will present to attendees.

-- March 18: Invest Northwest CEO & Investor Forum at the Bell Harbor

International Conference Center, 2211 Alaskan Way, Pier 66 in Seattle,

Wash. Dr. Ken Mohler, co-founder and senior vice president of Research

and Development, is scheduled to present at 11:20 a.m. PDT. The

presentation will be available via audio webcast at

http://www.wsw.com/webcast/in6/trbn/.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIPtm, therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended Sept. 30, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals, Inc.

Jim DeNike

Senior Director, Corporate Communications

206-838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Jenny Moede

Senior Vice President

503-443-7000

jmoede@wagged.com TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Martek Announces First Quarter 2008 Financial Results
2. HealthFitness Announces 2007 Fourth Quarter and Full-Year Results
3. Relax The Back Announces Record Growth in 2007; Executives Bullish on Specialty Retailers Prospects for 2008
4. AHRQ Announces New Members to U.S. Preventive Services Task Force
5. ADAMS Announces the Addition of Dani Barfield to the Firms Staff as Associate Project Manager
6. Trevena, Inc. Announces $24 Million Series A Financing
7. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
8. eDiets.com(R) Announces Q4 and Year End 2007 Results
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
10. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
11. Smith & Nephew Announces Breakthrough VERILAST(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: